Skip to main content
×
×
Home

Tolerance and safety of the potentially probiotic strain Lactobacillus rhamnosus PRSF-L477: a randomised, double-blind placebo-controlled trial in healthy volunteers

  • Richèle D. Wind (a1), Hermien Tolboom (a1) (a2), Ingo Klare (a3), Geert Huys (a4) and Jan Knol (a1)...
Abstract

In Europe, the species Lactobacillus rhamnosus is currently on the Qualified Presumption of Safety list used by the European Food Safety Authority (EFSA) for internal safety assessment, but according to the EFSA the species should remain a topic of surveillance. In the present study, the safety and tolerance of the potentially probiotic strain L. rhamnosus PRSF-L477 was investigated in a placebo-controlled double-blind volunteer trial following FAO/WHO guidelines. A total of thirty-four subjects received daily doses of 1 × 1011 colony-forming units (cfu) of L. rhamnosus PRSF-L477 (n 17) or placebo (n 17) for a period of 3 weeks, followed by a wash-out period of another 3 weeks. A questionnaire on gastrointestinal tolerance and a diary was kept daily to record compliance throughout these 6 weeks. Faecal and blood samples were collected for microbiological and haematological analysis. The recorded gastrointestinal symptoms, defecation frequency and stool consistency were not influenced indicating that L. rhamnosus PRSF-L477 was well tolerated. The species L. rhamnosus was detected in the faeces of sixteen out of seventeen subjects of the probiotic group during the intervention period. Using pulsed-field gel electrophoresis, re-isolates of L. rhamnosus PRSF-L477 were confirmed in nine of these subjects. Antibiotic susceptibility profiles of these re-isolates were unchanged compared with PRSF-L477. No clinically relevant changes in blood parameters such as liver and kidney function and no serious adverse events appeared during and after administration. Therefore, we conclude that L. rhamnosus PRSF-L477 can safely be administrated to healthy subjects at a daily dose of 1 × 1011 cfu.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Tolerance and safety of the potentially probiotic strain Lactobacillus rhamnosus PRSF-L477: a randomised, double-blind placebo-controlled trial in healthy volunteers
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Tolerance and safety of the potentially probiotic strain Lactobacillus rhamnosus PRSF-L477: a randomised, double-blind placebo-controlled trial in healthy volunteers
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Tolerance and safety of the potentially probiotic strain Lactobacillus rhamnosus PRSF-L477: a randomised, double-blind placebo-controlled trial in healthy volunteers
      Available formats
      ×
Copyright
Corresponding author
*Corresponding author: Dr R. D. Wind, fax +31 317 466500, email richele.wind@danone.com
References
Hide All
1Borriello, SP, Hammes, WP, Holzapfel, W, et al. (2003) Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 36, 775780.
2Bernardeau, M, Vernoux, JP, Henri-Dubernet, S, et al. (2008) Safety assessment of dairy microorganisms: the Lactobacillus genus. Int J Food Microbiol 126, 278285.
3Cannon, JP, Lee, TA, Bolanos, JT, et al. (2005) Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 24, 3140.
4Salminen, MK, Rautelin, H, Tynkkynen, S, et al. (2004) Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 38, 6269.
5Gasser, F (1994) Safety of lactic acid bacteria and their occurence in human clinical infections. Bull Inst Pasteur 92, 4567.
6Salminen, MK, Tynkkynen, S, Rautelin, H, et al. (2002) Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35, 11551160.
7Land, MH, Rouster-Stevens, K, Woods, CR, et al. (2005) Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115, 178181.
8Kunz, A & Farichok, MP (2004) Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome: the authors' reply. J Pediatr Gastroenterol Nutr 39, 437.
9Mackay, AD, Taylor, MB, Kibbler, CC, et al. (1999) Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 5, 290292.
10Rautio, M, Jousimies-Somer, H, Kauma, H, et al. (1999) Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 28, 11591160.
11Dekker, JW, Wickens, K, Black, PN, et al. (2009) Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. animalis HN019 in human infants aged 0–2 years. Int Dairy J 19, 149154.
12Kukkonen, K, Savilahti, E, Haahtela, T, et al. (2008) Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics 122, 812.
13Scalabrin, DM, Johnston, WH, Hoffman, DR, et al. (2009) Growth and tolerance of healthy term infants receiving hydrolyzed infant formulas supplemented with Lactobacillus rhamnosus GG: randomized, double-blind, controlled trial. Clin Pediatr (Phila) 48, 734744.
14Salminen, MK, Tynkkynen, S, Rautelin, H, et al. (2004) The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study. HIV Clin Trials 5, 183191.
15Jacobsen, L, Wilcks, A, Hammer, K, et al. (2007) Horizontal transfer of tet(M) and erm(B) resistance plasmids from food strains of Lactobacillus plantarum to Enterococcus faecalis JH2-2 in the gastrointestinal of gnotobiotic rats. FEMS Microbiol Ecol 59, 158166.
16Teuber, M, Meile, L & Schwarz, F (1999) Acquired antibiotic resistance in lactic acid bacteria from food. Antonie Van Leeuwenhoek 76, 115137.
17Ammor, MS, Belen Florez, A & Mayo, B (2007) Antibiotic resistance in non-enterococcal lactic acid bacteria and bifidobacteria. Food Microbiol 24, 559570.
18Dahl, KH, Mater, DD, Flores, MJ, et al. (2007) Transfer of plasmid and chromosomal glycopeptide resistance determinants occurs more readily in the digestive tract of mice than in vitro and exconjugants can persist stably in vivo in the absence of glycopeptide selection. J Antimicrob Chemother 59, 478486.
19Saarela, M, Maukonen, J, von Wright, A, et al. (2007) Tetracycline susceptibility of the ingested Lactobacillus acidophilus LaCH-5 and Bifidobacterium animalis subsp. lactis Bb-12 strains during antibiotic/probiotic intervention. Int J Antimicrob Agents 29, 271280.
20Mater, DD, Langella, P, Corthier, G, et al. (2008) A probiotic Lactobacillus strain can acquire vancomycin resistance during digestive transit in mice. J Mol Microbiol Biotechnol 14, 123127.
21European Food Safety Authority (2008) Scientific Opinion of the Panel on Biological Hazards on a request of EFSA on the maintenance of the list of QPS microorganisms intentionally added to food or feed. The EFSA Journal 923, 1–48. http://www.efsa.europa.eu/cs/BlobServer/Scientific_Opinion/biohaz_op_ej923_qps_summary_en.pdf?ssbinary=true.
22Vankerckhoven, V, Huys, G, Vancanneyt, M, et al. (2008) Biosafety assessment of probiotics used for human consumption: recommendations from the PROSAFE project. Trends Food Sci Technol 19, 102114.
23Rosenfeldt, V, Benfeldt, E, Nielsen, SD, et al. (2003) Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 111, 389395.
24Tannock, GW, Munro, K, Harmsen, HJ, et al. (2000) Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol 66, 25782588.
25Jacobsen, CN, Rosenfeldt Nielsen, V, Hayford, AE, et al. (1999) Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol 65, 49494956.
26Verdenelli, MC, Ghelfi, F, Silvi, S, et al. (2009) Probiotic properties of Lactobacillus rhamnosus and Lactobacillus paracasei isolated from human faeces. Eur J Nutr 48, 355363.
27World Health Organization & Food and Agriculture Organization (2002) Guidelines for the Evaluation of Probiotics in Food. Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. London, Ontario, Canada. http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf.
28Braat, H, van den Brande, J, van Tol, E, et al. (2004) Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr 80, 16181625.
29Luyer, MD, Buurman, WA, Hadfoune, M, et al. (2005) Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock. Infect Immun 73, 36863692.
30Hartemink, R & Rombouts, FM (1999) Comparison of media for the detection of bifidobacteria, lactobacilli and total anaerobes from faecal samples. J Microbiol Methods 36, 181192.
31Hartemink, R, Domenech, VR & Rombouts, FM (1997) LAMVAB – a new selective medium for the isolation of lactobacilli from faeces. J Microbiol Methods 29, 7784.
32Scardovi, V (1986) Genus Bifidobacterium Orla-Jensen (1986). In Bergey's Manual of Systematic Bacteriology, pp. 14181434 [Sneath, PHA, Mair, NS and Sharpe, ME, et al. , editors]. Baltimore, MD: Williams & Wilkins.
33Bakker-Zierikzee, AM, Alles, MS, Knol, J, et al. (2005) Effects of infant formula containing a mixture of galacto- and fructo-oligosaccharides or viable Bifidobacterium animalis on the intestinal microflora during the first 4 months of life. Br J Nutr 94, 783790.
34Haarman, M & Knol, J (2006) Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula. Appl Environ Microbiol 72, 23592365.
35Vancanneyt, M, Huys, G, Lefebvre, K, et al. (2006) Intraspecific genotypic characterization of Lactobacillus rhamnosus strains intended for probiotic use and isolates of human origin. Appl Environ Microbiol 72, 53765383.
36Klare, I, Konstabel, C, Muller-Bertling, S, et al. (2005) Evaluation of new broth media for microdilution antibiotic susceptibility testing of lactobacilli, pediococci, lactococci, and bifidobacteria. Appl Environ Microbiol 71, 89828986.
37Harty, DW, Oakey, HJ, Patrikakis, M, et al. (1994) Pathogenic potential of lactobacilli. Int J Food Microbiol 24, 179189.
38Svedlund, J, Sjodin, I & Dotevall, G (1988) GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33, 129134.
39Whelan, K, Judd, PA & Taylor, MA (2004) Assessment of fecal output in patients receiving enteral tube feeding: validation of a novel chart. Eur J Clin Nutr 58, 10301037.
40Van Aerde, J, Alarcon, P, Lam, W, et al. (2003) Tolerance and safety of energy-dense enteral formulae for young children. Int Pediatr 18, 9599.
41Makelainen, H, Tahvonen, R, Salminen, S, et al. (2003) In vivo safety assessment of two Bifidobacterium longum strains. Microbiol Immunol 47, 911914.
42Choi, SS, Kang, BY, Chung, MJ, et al. (2005) Safety assessment of potential lactic acid bacteria Bifidobacterium longum SPM1205 isolated from healthy Koreans. J Microbiol 43, 493498.
43Harty, DW, Patrikakis, M, Hume, EB, et al. (1993) The aggregation of human platelets by Lactobacillus species. J Gen Microbiol 139, 29452951.
44Hatakka, K, Holma, R, El-Nezami, H, et al. (2008) The influence of Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS on potentially carcinogenic bacterial activity in human colon. Int J Food Microbiol 128, 406410.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

British Journal of Nutrition
  • ISSN: 0007-1145
  • EISSN: 1475-2662
  • URL: /core/journals/british-journal-of-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed